Literature DB >> 76395

Plasma levels of 8-methoxypsoralen and phototoxicity studies during PUVA treatment of psoriasis with meladinin tablets.

P Thune.   

Abstract

A new tablet formulation of 8-methoxypsoralen was used in PUVA treatment for psoriasis. The 8-Mop plasma level showed a maximum at about 1 hour after ingestion (mean values: 1/2 hr, 284 microgram/1; 1 hr, 275 microgram/1; 1 1/2 hr, 198 microgram/1; 2 hrs, 129 microgram/1). Phototoxicity tests showed the optimal time for exposure to be about 1 hour after peroral intake of 8-MOP.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 76395

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   4.437


  8 in total

1.  [8-Methoxypsoralen (8-MOP)-a new galenic form and its relation to 8-MOP serum levels (author's transl)].

Authors:  V Nitsche; M Raff; H Bardach
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

2.  Difference in bioavailability between two brands of 8-methoxypsoralen and its impact on the clinical response in psoriatic patients.

Authors:  M J Herfst; F A De Wolff
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

3.  Microenema of 8-methoxypsoralen in photochemotherapy of psoriasis.

Authors:  A H Siddiqui; L Stolk; H R Korthals Altes-Levij van Vinninghe; A Kammeijer; R H Cormane
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

4.  Intraindividual variations of 8-methoxypsoralen plasma levels.

Authors:  M Schäfer-Korting; H C Korting
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

5.  Variations in skin photosensitization during repeated oral 8-methoxypsoralen medication.

Authors:  C T Jansén; G Wilén; R Paul
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

Review 6.  Clinical pharmacokinetics of methoxsalen and other psoralens.

Authors:  F A de Wolff; T V Thomas
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

7.  Pharmacokinetic and clinical comparison of two 8-methoxypsoralen brands.

Authors:  K E Andersen; T Menne; M Gammeltoft; N Hjorth; E Larsen; P Solgaard
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

8.  Pharmacokinetics of 8-methoxypsoralen in serum and suction blister fluid.

Authors:  J Lauharanta; T Juvakoski; L Kanerva; A Lassus
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.